ELTROMBOPAG TABLETS

Description

Eltrombopag
tablets are a specialized medication formulated for individuals diagnosed
with thrombocytopenia, a condition characterized by an abnormally low number
of platelets in the blood. This pharmaceutical product aims to aid patients
who are non-responsive to or intolerant of first-line therapies by
stimulating the production of platelets to reduce the risk of bleeding.

Key Features:

– Effective Platelet Production: Eltrombopag acts as a thrombopoietin
receptor agonist, effectively stimulating the body’s natural production of
platelets. This is vital for patients with chronic immune thrombocytopenia
(ITP) and chronic Hepatitis C, helping to manage and increase platelet counts
in the bloodstream.

– Proven Results: Clinically tested and approved, eltrombopag has
demonstrated significant efficacy in increasing platelet counts, which is
crucial in preventing severe bleeding events and improving the overall
quality of life for patients.

– Convenient Dosage Forms: These tablets come in multiple strengths,
enabling healthcare providers to tailor the dosage in accordance with the
individual needs of each patient, ensuring personalized and effective
treatment plans.

Clinical Applications:

– Refractory Chronic ITP: Intended for adults and children with ITP who
have shown insufficient response to other treatments, providing a vital
option for those who have been unresponsive to conventional therapies.

– Hepatitis C-associated thrombocytopenia: Effective in managing
thrombocytopenia in patients with chronic Hepatitis C to allow initiation and
maintenance of interferon-based therapy.

– Severe Aplastic Anemia: Eltrombopag is utilized in certain cases for
patients with severe aplastic anemia who have not responded adequately to
immunosuppressive therapy.

Administration and Usage:

– Typically administered orally as directed by a healthcare provider.
– Not intended as a first-line treatment; carefully consider treatment
options and consult with a healthcare professional to determine the
suitability of this medication.
– Regular monitoring of platelet counts and liver function tests is
recommended during the course of treatment with eltrombopag.

Important Considerations:

– Contraindications: Eltrombopag is contraindicated in patients
hypersensitive to any component of the product.
– Side Effects: Potential side effects include headache, nausea, and an
increase in liver enzymes. Any adverse reactions should be promptly reported
to a healthcare provider.

Eltrombopag tablets provide a meaningful treatment option derived from
deliberate scientific research designed for individuals dealing with the
challenges of thrombocytopenia. While use should be closely monitored, it
offers significant hope and a chance for improved outcomes for qualifying
patients.